<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: The purpose of this study was to evaluate midkine, multipotential cytokine, and growth factor in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) stratified by <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> location </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Midkine was assessed immunoenzymatically in paired cancerous and noncancerous tissues from 53 CRCs and referred to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> stage, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> location, and size, and circulating cytokine levels </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Midkine was higher in cancerous versus noncancerous tissue in 98 % cases (424.2 vs. 31.1 pg/mg, p &lt; 0.0001) </plain></SENT>
<SENT sid="3" pm="."><plain>Mean fold increase was 30.1; in 72.5 %, the relative increase was over fivefold </plain></SENT>
<SENT sid="4" pm="."><plain>Midkine upregulation was more pronounced in colon than in rectum (fold increase: 36.6 vs. 12.7, p = 0.005) due to higher midkine level in noncancerous rectal than colonic tissue (45.5 vs. 26.2 pg/mg, p = 0.074) </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> location affected midkine association with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> stage </plain></SENT>
<SENT sid="6" pm="."><plain>Midkine fold change was higher in advanced stages of <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancers</z:e> (16.8 vs. 5.3, respectively in III/IV vs. I/II, p = 0.013), while it tended to be lower in colonic ones (25.3 vs. 47.8, p = 0.134) </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, fold change in midkine level was higher in rectal N1 than N0 <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> (17.3 vs. 16.5, p = 0.032), while it tended to be lower in <z:e sem="disease" ids="C0007102" disease_type="Neoplastic Process" abbrv="">colonic cancers</z:e> (23.6 vs. 50.1, p = 0.085) </plain></SENT>
<SENT sid="8" pm="."><plain>Midkine negatively correlated with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> size (r = 0.40, p = 0.017), while it tended to positively correlate with its serum levels (r = 0.45, p = 0.081) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Midkine is differently expressed in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> arising from colonic and rectal mucosa, where it may play diverse roles in <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>High midkine expression in noncancerous rectal mucosa might contribute to, a characteristic for <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancers</z:e>, higher incidence of local recurrence </plain></SENT>
<SENT sid="11" pm="."><plain>Divergent expression of midkine and its association pattern ought to be taken into account while designing midkine-directed therapies for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>